RHHBY - Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative | Benzinga
What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment.
As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with the market’s recent recovery, Cramer encourages focus on stocks that stand to gain from these drugs.
Immediate beneficiaries include leading GLP-1 companies Eli Lilly And Co (NYSE:LLY) and manufacturer of Ozempic, Novo Nordisk A/S (NYSE:NVO). Cramer touched on potential stock gains as these drugs could potentially treat conditions beyond obesity and diabetes, such as heart disease, kidney disease, and alcoholism.
Other potential GLP-1 opportunities include high-protein food manufacturers like Tyson Foods or Hormel Foods, and construction companies like Jacobs Solutions specializing in creating pharmaceutical manufacturing facilities. The apparel sector, with brands like Levi’s already benefitting from changes in customer sizes, also holds potential, Cramer suggests.
“When the market was ugly, everyone was worried about how much money ...